Enlivex Therapeutics (ENLV) Q3 2024 earnings summary

Executive summary

• Enlivex Therapeutics is a clinical-stage company focused on macrophage reprogramming immunotherapy, with Allocetra™ as its lead candidate targeting sepsis, osteoarthritis, and psoriatic arthritis.

• Strategic reprioritization in 2023 shifted focus to inflammatory and autoimmune indications, reducing workforce by 50% and ceasing internal oncology development.

• Positive interim data from Phase I/II knee osteoarthritis trial and initiation of Phase II and psoriatic arthritis trials were key milestones in 2024.

• Sale of manufacturing facility and May 2024 equity offering extended cash runway, with management expecting funding through end of 2026.

Financial highlights

• Net loss for nine months ended September 30, 2024 was $9.8M, down 51% from $20.0M in the same period of 2023; Q3 2024 net loss was $2.6M, down 56% year-over-year.

• Research and development expenses for nine months were $7.2M, down 51% year-over-year; Q3 R&D expenses were $2.3M, down 46%.

• General and administrative expenses for nine months were $2.9M, down 37% year-over-year; Q3 G&A expenses were $0.8M, down 40%.

• Operating loss for nine months was $10.3M, a 46% decrease year-over-year; Q3 operating loss was $3.1M, down 45%.

• Finance income for nine months was $418K, compared to a $913K expense in 2023, mainly due to higher interest income and lower FX losses.

• Cash, cash equivalents, restricted cash, and short-term deposits totaled approximately $25M as of September 30, 2024.

Outlook and guidance

• Management expects existing cash resources to fund operations through the end of 2026, supporting key clinical milestones.

• Topline data from the randomized Phase I/II knee osteoarthritis trial expected by Q3 2025.

• Company anticipates continued operating losses and will require additional funding for future development and commercialization.